DARE stock: buy or sell?

DARE stock price: $1.66 2.47% At close on January 17th, 2020

Updated on:
January 17th, 2020


Shares of Dare Bioscience ended yesterday at $1.66 and rose a remarkable 2.47%. On Tuesday DARE collapsed a dreadful -20.44%. On Wednesday DARE climbed an exceptional 11.61%. With Friday, it's been 3 green days in a row, soaring $0.29 or 17.58%.

Daré Bioscience, Inc. develops and commercializes product for women's reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.

Should I buy DARE stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Dare Bioscience stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Dare Bioscience stock a buy?

Financial institutions and banks publish stock ratings everyday. At Stocks2.com, we detected 2 ratings published for DARE stock in the last month.

Is DARE a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-4-4Maxim Groupn/aBuy

DARE stock analysis

Daily outlook

Dare Bioscience ended yesterday at $1.66 and rose a remarkable 2.47%.

Shares of Dare Bioscience closed yesterday at $1.66 and rose a remarkable 2.47%. Since last Monday when DARE stock price broke up the SMA200d line, it gained $0.82 (97.62%). From a daily perspective, DARE is in a short term uptrend after plotting its last bottom ($0.80, on Jan/7) higher than the previous bottom, and its last top ($2.22, on Monday) also over the previous top. Now trading in between its last bottom and last top DARE might consolidate in a plain range, waiting to break out over $2.22 or down under $0.80. On October, SMA50d and SMA100d crossed up triggering a rise of 97.62%.

DARE stock chart (daily)

Weekly outlook

Dare Bioscience shares crossed up the SMA line of 200d, closing at $1.66. For 3 weeks in a row, price climbed and marked a profit of 100.00%.

Weekly chart tells us that price finally broke over the resistance at $0.90 and continued climbing.

DARE stock chart (weekly)

DARE stock price history

DARE IPO was on April 10th, 2014 at $71.00 per share1. Since then, DARE stock declined a -97.70%, with a yearly average of -19.50%.

1: Adjusted price after possible price splits or reverse-splits.

DARE stock historical price chart

DARE stock reached 52-week highs on March at $3.25, and all-time highs 2015-03-19 with a price of 108.7.

DARE stock price target is $3.00

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price forecast for Dare Bioscience stock was posted in the last 30 days:
DARE stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-4-4Maxim GroupReiteratesn/a$3.00-
(in average)$0.00$3.000.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on April, Dare Bioscience . Unfortunately, reported EPS is not yet available in our database.
DARE earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2014, last anual revenues report draw an exceptional growth of 857.50% to $0.77 million USD. When comparing 2016 vs 2014, similarly, profit margin (that is, the net income divided by revenues) climbed a 24,046.30% to -5,131.20%.

DARE annual Sales and Income evolution
2013$6.00 M-$0.00 M0.0%-
2014$0.08 M-98.67%$-23.34 M-29177.5%0.00%
2016$0.77 M857.50%$-39.31 M-5131.2%68.39%

Quarterly financial results

Reported quarter earnings marked $-2.92 million with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Dare Bioscience sales marked a tight movement and stayed stable a nan%. Looking back to recent quarterly results, Dare Bioscience posted 7 negative quarters in a row.
DARE quarterly Sales and Income evolution
2017-Q1$1,192.00 M-$0.00 M0.0%-
2017-Q2$642.00 M-46.14%$0.00 M0.0%0.00%

Dare Bioscience ownership

When you are planning to invest in shares of a stock, it's worth to have a look its ownership structure.

Dare Bioscience shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 18.95% of all shares.

In case of Dare Bioscience stock, 4.83% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for DARE stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

Market cap$32.7 M$540.0 M$682.6 M$1.3 B$4.0 B
Total shares19.7 M54.8 M149.7 M15.4 M175.9 M
Float shares14.4 M43.4 M125.0 M7.4 M174.1 M
  - Institutional holdings (%)4.8%106.1%70.1%92.2%102.5%
  - Insider holdings (%)18.9%3.1%1.4%10.8%1.2%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

DARE summary

Friday, January 17th, 2020
Day range$1.62 - $1.68
Previous close$1.62
Session gain2.47%
Average true range$0.20
50d mov avg$0.90
100d mov avg$0.85
200d mov avg$0.87
Daily patternlt06a
Weekly pattern lb01c

Dare Bioscience performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected Clovis Oncology, ImmunoGen, Madrigal Pharmaceuticals, Nektar, Seattle Genetics and Spectrum Pharmaceuticals as the bechmarking frame for Dare Bioscience stock.
DAREDare Bioscience104.94%107.50%93.02%
CLVSClovis Oncology194.91%-10.05%-58.96%
MDGLMadrigal Pharmace...-1.20%-7.00%-28.88%
SGENSeattle Genetics24.71%45.20%48.08%
SPPISpectrum Pharmace...-59.65%-58.73%-70.30%

Dare Bioscience competitors

We picked a few stocks to conform a list of Dare Bioscience competitors to examine if you are interested in investing in DARE: